ArticleNature2025
NASP modulates histone turnover to drive PARP inhibitor resistance.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer.Nature communications · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- NASP functions in the cytoplasm to prevent histone H3 aggregation during early embryogenesis.The Journal of cell biology · 2026Article
- RAD21 regulation of the enhancer-promoter chromatin loop of RAD51 promotes PARPi resistance in ovarian cancer.Journal of translational medicine · 2026Article
- PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis.Biomedicines · 2026Article
- PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge.Experimental & molecular medicine · 2026Review
- Targeted inhibition of PARP-1 in pulmonary epithelial cells and macrophages via SPA-functionalized microparticles attenuates sepsis-induced lung injury.Materials today. Bio · 2026Article
- Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance.Pharmaceutics · 2026Review
- Fork Reversal Safeguards Epigenetic Inheritance During Replication Stress.Research square · 2026Article
- Chromatin adaptation and histone remodeling as mechanisms of PARP inhibitor resistance and therapeutic vulnerability.Frontiers in pharmacology · 2026Review
- The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.Frontiers in pharmacology · 2026Review
- Proteome-widebioRxiv : the preprint server for biology · 2025Article
- NASP functions in the cytoplasm to prevent histone H3 aggregation during early embryogenesis.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Sarah C MoserDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-1678-4079
Anna KhalizievaDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Josef RoehsnerDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Elisabeth PottendorferDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Milo L KapteinDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0009-0009-5863-9169
Giulia RicciHubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, Netherlands.
Vivek BhardwajInstitute of Biodynamics and Biocomplexity, Utrecht University, Utrecht, Netherlands.
Onno B BleijerveldMass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-9395-2347
Liesbeth HoekmanMass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-3552-6390
Ingrid van der HeijdenDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0003-2849-8253
Simone di SanzoMOLEQLAR Analytics GmbH, Munich, Germany.
Alexander FishDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.
Aleksandra ChikunovaDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-2818-0539
Judith H I HaarhuisDivison of Cell Biology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Roel OldenkampDivison of Cell Biology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Luisa Robbez-MassonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Justin SprengersMouse Clinic for Cancer and Aging Research, Intervention Unit, Netherlands Cancer Institute, Amsterdam, Netherlands.
Daniel J VisDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Lodewyk F A WesselsDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-1656-6995
Marieke van de VenMouse Clinic for Cancer and Aging Research, Intervention Unit, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0001-6779-9353
Stephen J PettittThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Andrew N J TuttThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0001-8715-2901
Christopher J LordThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-3226-0515
Benjamin D RowlandDivison of Cell Biology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0002-0694-8463
Moritz Völker-AlbertMOLEQLAR Analytics GmbH, Munich, Germany.
Francesca MattiroliHubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, Netherlands.ORCID 0000-0002-1574-7217
Thijn R BrummelkampOncode Institute, Utrecht, Netherlands.ORCID 0000-0002-3066-7071
Abdelghani MazouziOncode Institute, Utrecht, Netherlands. a.mazouzi@nki.nl.ORCID 0000-0003-0298-6304
Jos JonkersDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands. j.jonkers@nki.nl.ORCID 0000-0002-9264-9792
Funding
No grant is acknowledged in the PubMed record.
Abstract
The poly(ADP-ribose) polymerase inhibitor (PARPi) class of drugs represents a remarkable advance in the treatment of patients with homologous recombination-deficient tumours, but resistance remains a challenge
Indexed as
Drug Resistance, NeoplasmHistonesNuclear ProteinsPoly(ADP-ribose) Polymerase InhibitorsAnimalsCell Line, TumorChromatinDNA DamageDNA ReplicationFemaleHumansMicePoly (ADP-Ribose) Polymerase-1Protein StabilityChromatinHistonesNuclear ProteinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitors
Identifiers
PMID
40804522What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.